Dexamethasone — Class II drug recall D-0177-2021
Terminated recall by Imprimis NJOF, LLC, reported 2021-01-06, distributed nationwide. Lack of assurance of sterility: 13 vials were discovered to have faulty crimps.
| Recall number | D-0177-2021 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Imprimis NJOF, LLC, Ledgewood, NJ, United States |
| Recall initiated | 2020-12-17 |
| Classified | 2020-12-30 |
| Reported by FDA | 2021-01-06 |
| Terminated | 2023-08-23 |
| Distributed | Nationwide (US) |
| Quantity | 6,520 vials |
| Reason classes | sterility |
| Lot numbers | 20JUN010 |
| Expiration dates | 2021-05-12 |
Product
Dexamethasone - Moxifloxacin PF Injection (1/5) mg/mL, Imprimis Rx Volume: 1mL/vial, Imprimis NJOF, LLC. 1705 Route 46 West, Unit 6B Ledgewood, NJ - 07852 (844)446-6979
Reason for recall
Lack of assurance of sterility: 13 vials were discovered to have faulty crimps.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0177-2021. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.